一种新药佐列武生（zorevunersen）能将患有Dravet综合征的儿童癫痫发作减少多达90%，为变革性治疗带来希望。 A new drug, zorevunersen, reduces seizures by up to 90% in children with Dravet syndrome, offering hope for a transformative treatment.

在治疗Dravet综合症(一种影响儿童的严重的遗传性癫痫)方面,一种新的药物,即甲状腺素,正在显示出巨大的前景。 A new drug, zorevunersen, is showing significant promise in treating Dravet syndrome, a severe genetic epilepsy affecting children. 通过脊髓注射, 促进大脑中的健康通道, 在早期试验中, 减少发作高达90%. Administered via spinal injection, it boosts healthy sodium channels in the brain, reducing seizures by up to 90% in early trials. 在英国和美国,年仅两岁的儿童经历了显著改善,包括缉获量减少,生活质量提高。 Children as young as two in the UK and US have experienced dramatic improvements, including fewer seizures and better quality of life. 目前正在进行第三阶段的试验,以确认长期的安全和有效性,专家们称试验结果对受病情影响的家庭来说是一次变革性突破。 Phase Three trials are underway to confirm long-term safety and effectiveness, with experts calling the results a transformative breakthrough for families affected by the condition.